Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Stock-Based Comp

Similar metrics at other companies

Spyre Therapeutics, Inc. logo
SYREReportable Segment — Stock-Based Comp
$12.81M+44.6%
Ouster logo
OUSTReportable Segment — Stock-Based Comp
$1.69M+6.0%
DraftKings Inc. logo
DKNGReportable Segment — Stock-Based Comp
$82.55M-2.5%
CareTrust logo
CTREReportable Segment — Stock-Based Comp
$3.02M-0.1%
Energy Vault Holdings logo
NRGVReportable Segment — Stock-Based Comp
$4.37M-51.4%
Evolv Technologies Holdings, Inc. logo
EVLVReportable Segment — Stock-Based Comp
$6.85M+23.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$973.83M-14.0%
Enterprise value$1.24B+4.9%
P/E189.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Adjusted research and development (1)25,36223,101
Adjusted selling and marketing (1)58,16655,571
Adjusted general and administrative (1)25,71220,609
Stock-based compensation (1)13,53914,553
Amortization of acquired intangible assets14,32214,322
Changes in the fair value of contingent consideration(2,277)(2,675)
Legal settlement7,000
Other (2)8801,862

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — stock-based comp?
Pacira BioSciences, Inc. (PCRX) reported business segments — stock-based comp of $13.54M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — stock-based comp changed year-over-year?
Pacira BioSciences, Inc.'s business segments — stock-based comp decreased by 7.0% year-over-year, from $14.55M to $13.54M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — stock-based comp?
Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — stock-based comp has grown at a 6.1% compound annual growth rate (CAGR), from $48.09M to $57.5M.
What does business segments — stock-based comp mean?
Measures the non-cash expense recognized for equity-based awards granted to employees within the reportable segment. It is a critical component of total compensation and reflects the cost of aligning employee incentives with shareholder interests.

Ask your AI about Pacira BioSciences, Inc.'s business segments — stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude